Skip to main content
NVDA-0.18%AAPL-0.21%GOOGL+0.59%MSFT-0.44%AMZN-0.15%TSM-1.68%SPCX+0.43%AVGO-0.97%META-0.47%TSLA-0.02%SKHY-5.20%MU-0.52%BRK-B+0.06%LLY-0.10%JPM-0.32%WMT-0.09%AMD-3.36%V-0.05%XOM+0.61%ASMLa-1.66%JNJ-0.27%INTC-5.57%0700.HK+0.68%MA-0.38%1398.HK+0.03%ABBV+1.62%BAC-0.18%ORCL-5.23%CVX-0.50%CSCO-1.82%COST-0.02%KO+0.32%LRCX-5.65%CAT-1.29%AP2d-1.55%AMAT-3.17%0005.HK-1.12%HSBA.L-1.30%UNH-1.22%PG+0.25%DELL-5.35%GE-0.39%MS-1.22%1816.HK-28.77%3988.HK+1.05%0857.HK-1.39%NFLX-0.03%HD-1.53%0939.HK-0.03%GS-0.88%NZDJPY-2.17%AUDJPY-1.78%CHFJPY-1.74%EURJPY-1.38%CADJPY-1.37%USDJPY-1.36%GBPJPY-1.28%GBPNZD+0.89%NZDUSD-0.85%EURNZD+0.83%NZDCAD-0.81%NZDSGD+0.57%USDTHB+0.54%GBPAUD+0.48%NZDCHF-0.47%GBPCHF+0.44%AUDCAD-0.43%AUDUSD-0.43%AUDNZD+0.42%NZDMXN+0.41%GBPTRY+0.41%EURAUD+0.40%USDCHF+0.40%EURCHF+0.35%CADCHF+0.35%USDTRY+0.34%GBPHKD+0.32%AUDNOK+0.31%NOKJPY-0.30%GBPMXN-0.28%EURZAR-0.25%USDZAR-0.25%AUDDKK+0.22%PLNJPY-0.21%AUDSGD+0.19%SGDJPY-0.18%USDMXN-0.17%USDILS+0.16%GBPZAR-0.14%CHFNOK+0.12%USDSEK-0.10%EURSEK-0.09%EURNOK+0.09%USDNOK+0.09%EURCNH-0.08%EURCZK-0.08%EURGBP-0.08%GBPCAD+0.08%GBPSGD+0.07%GBPUSD+0.07%CHFSEK-0.06%EURSGD-0.04%USDCOP-0.04%AUDCHF-0.04%USDSGD-0.04%EURUSD-0.03%USDCAD+0.03%USDCNH+0.03%USDHKD+0.01%EURPLN-0.01%EURCAD-0.01%EURHKD-0.01%EURDKK-0.01%USDDKK0.00%USDPLN0.00%CHFSGD0.00%UKOIL-2.79%USOIL-2.62%XPTUSD+1.22%COTTON-1.05%S1-0.99%C1-0.94%HG1+0.87%GAUUSD+0.77%XAUUSD+0.77%W1-0.61%GAGUSD+0.48%XAGUSD+0.48%BTCUSD-1.34%ETHUSD-0.07%USDTUSD-0.04%XRPUSD-3.17%SOLUSD-1.82%TRXUSDT-0.06%ZECUSDT-11.18%DOGEUSD-2.63%XMRUSDT-0.19%LINKUSD-2.39%XLMUSD-2.72%BCHUSDT-9.91%LTCUSD-0.36%UNIUSD+0.08%TONUSD+24.88%HBARUSDT-2.67%SUIUSD-4.55%TAOUSDT-7.27%DOTUSDT+3.16%AAVEUSD-2.08%ICPUSDT-0.97%ONDOUSDT-2.84%WLDUSDT-3.63%ATOMUSDT-5.35%ARBUSDT-3.29%JUPUSDT+0.04%INJUSDT-3.04%STXUSDT-7.08%FETUSDT-2.68%TIAUSDT-2.70%PYTHUSDT-1.51%SEIUSDT-6.02%IMXUSDT-5.44%WIFUSDT-5.87%GRTUSDT-5.23%OPUSDT-5.01%POLUSDT-5.49%IOTAUSDT-3.69%AXSUSDT-1.82%FARTCOINUSDT-2.79%EOSUSDT-3.15%DYDXUSDT-1.48%ORDIUSDT-1.27%GALAUSDT-5.34%NOTUSDT-2.97%RONINUSDT-2.64%NVDA-0.18%AAPL-0.21%GOOGL+0.59%MSFT-0.44%AMZN-0.15%TSM-1.68%SPCX+0.43%AVGO-0.97%META-0.47%TSLA-0.02%SKHY-5.20%MU-0.52%BRK-B+0.06%LLY-0.10%JPM-0.32%WMT-0.09%AMD-3.36%V-0.05%XOM+0.61%ASMLa-1.66%JNJ-0.27%INTC-5.57%0700.HK+0.68%MA-0.38%1398.HK+0.03%ABBV+1.62%BAC-0.18%ORCL-5.23%CVX-0.50%CSCO-1.82%COST-0.02%KO+0.32%LRCX-5.65%CAT-1.29%AP2d-1.55%AMAT-3.17%0005.HK-1.12%HSBA.L-1.30%UNH-1.22%PG+0.25%DELL-5.35%GE-0.39%MS-1.22%1816.HK-28.77%3988.HK+1.05%0857.HK-1.39%NFLX-0.03%HD-1.53%0939.HK-0.03%GS-0.88%NZDJPY-2.17%AUDJPY-1.78%CHFJPY-1.74%EURJPY-1.38%CADJPY-1.37%USDJPY-1.36%GBPJPY-1.28%GBPNZD+0.89%NZDUSD-0.85%EURNZD+0.83%NZDCAD-0.81%NZDSGD+0.57%USDTHB+0.54%GBPAUD+0.48%NZDCHF-0.47%GBPCHF+0.44%AUDCAD-0.43%AUDUSD-0.43%AUDNZD+0.42%NZDMXN+0.41%GBPTRY+0.41%EURAUD+0.40%USDCHF+0.40%EURCHF+0.35%CADCHF+0.35%USDTRY+0.34%GBPHKD+0.32%AUDNOK+0.31%NOKJPY-0.30%GBPMXN-0.28%EURZAR-0.25%USDZAR-0.25%AUDDKK+0.22%PLNJPY-0.21%AUDSGD+0.19%SGDJPY-0.18%USDMXN-0.17%USDILS+0.16%GBPZAR-0.14%CHFNOK+0.12%USDSEK-0.10%EURSEK-0.09%EURNOK+0.09%USDNOK+0.09%EURCNH-0.08%EURCZK-0.08%EURGBP-0.08%GBPCAD+0.08%GBPSGD+0.07%GBPUSD+0.07%CHFSEK-0.06%EURSGD-0.04%USDCOP-0.04%AUDCHF-0.04%USDSGD-0.04%EURUSD-0.03%USDCAD+0.03%USDCNH+0.03%USDHKD+0.01%EURPLN-0.01%EURCAD-0.01%EURHKD-0.01%EURDKK-0.01%USDDKK0.00%USDPLN0.00%CHFSGD0.00%UKOIL-2.79%USOIL-2.62%XPTUSD+1.22%COTTON-1.05%S1-0.99%C1-0.94%HG1+0.87%GAUUSD+0.77%XAUUSD+0.77%W1-0.61%GAGUSD+0.48%XAGUSD+0.48%BTCUSD-1.34%ETHUSD-0.07%USDTUSD-0.04%XRPUSD-3.17%SOLUSD-1.82%TRXUSDT-0.06%ZECUSDT-11.18%DOGEUSD-2.63%XMRUSDT-0.19%LINKUSD-2.39%XLMUSD-2.72%BCHUSDT-9.91%LTCUSD-0.36%UNIUSD+0.08%TONUSD+24.88%HBARUSDT-2.67%SUIUSD-4.55%TAOUSDT-7.27%DOTUSDT+3.16%AAVEUSD-2.08%ICPUSDT-0.97%ONDOUSDT-2.84%WLDUSDT-3.63%ATOMUSDT-5.35%ARBUSDT-3.29%JUPUSDT+0.04%INJUSDT-3.04%STXUSDT-7.08%FETUSDT-2.68%TIAUSDT-2.70%PYTHUSDT-1.51%SEIUSDT-6.02%IMXUSDT-5.44%WIFUSDT-5.87%GRTUSDT-5.23%OPUSDT-5.01%POLUSDT-5.49%IOTAUSDT-3.69%AXSUSDT-1.82%FARTCOINUSDT-2.79%EOSUSDT-3.15%DYDXUSDT-1.48%ORDIUSDT-1.27%GALAUSDT-5.34%NOTUSDT-2.97%RONINUSDT-2.64%
CL

Caris Life Sciences, Inc. (CAI)

NASDAQ • Healthcare

$24.04
+$0 (+0.0%)
Market closed

Last close at September 10, 2026 at 20:00 UTC

Open$23.2
Day Range$23.2 - $24.68
Avg. Volume (3M)5M
Market Cap$6.7B
P/E Ratio65.0
52 Week Range
$14.19$34.75
Next EarningsIn 54 daysNov 4, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$263.7M100%
Gross Profitminus cost of goods$179.5M68%
Operating Incomeminus R&D and overhead$26.9M10%

Fundamentals & Financials

Revenue (TTM)
$989.6M
Net Income (TTM)
$105.1M
EPS (TTM)
$0.37
ROA (TTM)
8.55%
Current Ratio
5.53
Dividend Yield
0%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+2700.0%Q1 2026$0.28
+91.0%Q2 2026$0
-139.2%Q3 2026$0
Next

Nov 4

in 54 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -139.2%

Caris Life Sciences’ revenue topped consensus as sales rose 45.4% to about $263.7 million in the second fiscal quarter of 2026 (period ended June 30, 2026), based on preliminary results reported August 5, 2026. Revenue of $263.7 million topped the $238.1 million estimate, +10.8%, and was up from about $181.4 million a year ago, with the company’s molecular profiling and oncology-focused diagnostics platform (including MI Profile and Caris Assure) underpinning the quarter’s scale. Profitability tracked higher volume, with gross profit of roughly $179.6 million translating to a gross margin of about 68%, while operating income came in near $26.9 million and operating margin stood around 10%. Cash generation was also positive, as Caris produced operating cash flow of about $61.4 million, and it repurchased roughly $21.4 million of stock during the period. Consensus for the next period calls for EPS of $0.02 on revenue of $255.5 million.

View full earnings history

About Caris Life Sciences, Inc.

Caris Life Sciences, Inc. develops molecular diagnostics and research tools for oncology, operating in healthcare and biotechnology and trading on the NASDAQ as CAI. Its platform analyzes tumor and blood samples to guide cancer treatment and support drug development, and it generated $812.0 million in revenue in FY2025.

Name
Caris Life Sciences, Inc.
CEO
David Dean Halbert
Website
www.carislifesciences.com
Industry
Healthcare
Year Founded
2008
Employees
1,846

Today's Snapshot

AI-generated

CAI ended the day slightly higher at 24.04, while its sector was weaker. Trading was lighter than usual, with volume about half of its usual level. Caris Life Sciences enlisted actor Kevin Costner for an early cancer detection campaign.

Trading Volume

Below 10d avg (5.2M)

2.6M

vs S&P 500 Today

Outperforming Market

+0.61%

Updated: September 10, 2026 at 20:29 UTC

Technical Indicators

4 Buy3 Neutral1 Sell
CAI exhibits a constructive trend backdrop with ADX indicating a strong trend while price sits above most medium and long-term moving averages, giving a bullish structural bias despite mixed short-term signals. Momentum is muted—RSI near neutral and MACD modestly positive—but oversold readings on Williams %R and a pivot just above the market suggest recent weakness may be contained. Volatility is elevated and on-balance volume is negative, so participation is uneven even as the trend strength supports upside. Technical takeaway: overall technicals point to a buy bias with caution on volume.
All signals
  • EMA (5 indicators)$20.58 - $24.70
    Buy
  • RSI (14)54.41
    Neutral
  • Stochastic %K (14, 3, 3)28.95
    Neutral
  • MACD Level (12, 26)1.22
    Neutral

Peers & Related Assets

MRNAModerna, Inc.
$136.62+0.7%
JAZZJazz Pharmaceuticals plc
$240.48-0.3%
HALOHalozyme Therapeutics, Inc.
$107-0.4%
CORTCorcept Therapeutics Incorporated
$114.92-0.7%
MDGLMadrigal Pharmaceuticals, Inc.
$533.12-2.5%
CYTKCytokinetics, Incorporated
$73.62-0.7%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.